Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) shares were down 14.4% during mid-day trading on Monday . The company traded as low as $1.19 and last traded at $1.19. Approximately 802,875 shares were traded during mid-day trading, an increase of 144% from the average daily volume of 329,035 shares. The stock had previously closed at $1.39.
Analysts Set New Price Targets
LUCD has been the topic of a number of analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $2.50 price target on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Cantor Fitzgerald reduced their price target on Lucid Diagnostics from $3.00 to $2.00 and set an "overweight" rating for the company in a research report on Friday, November 15th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Finally, Ascendiant Capital Markets dropped their target price on Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating for the company in a report on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $3.63.
View Our Latest Stock Analysis on LUCD
Lucid Diagnostics Stock Performance
The firm has a market capitalization of $75.96 million, a PE ratio of -1.12 and a beta of 1.34. The company has a fifty day simple moving average of $1.12 and a two-hundred day simple moving average of $0.95.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in LUCD. LPL Financial LLC raised its holdings in Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after purchasing an additional 12,035 shares in the last quarter. Lido Advisors LLC increased its position in shares of Lucid Diagnostics by 40.0% during the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after purchasing an additional 40,000 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock valued at $229,000 after purchasing an additional 65,964 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Lucid Diagnostics in the 4th quarter worth $67,000. Finally, Citadel Advisors LLC purchased a new position in Lucid Diagnostics during the 4th quarter worth $98,000. 74.01% of the stock is owned by institutional investors.
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Featured Articles
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
